After raising funds, we aim to expand across the country and enhance our defensibility in the market.

Internationalization is critical for growth; Facebook initially expanded too late into international markets, allowing clones to emerge while it focused on the U.S.

When we realized our competitors were shipping faster, we shifted our approach to product development, setting ambitious goals like building 25 new features in one month to drive innovation and focus.

We decided to launch our product through crowdfunding, as it was such an innovation that we couldn't compare it to anything else in the market.

Not having a lot of money forced us to innovate and focus on making every dollar count, which ultimately helped us grow faster than competitors who had more funding.

When we went public in 2021, we decided to save our funds instead of spending them immediately, anticipating tougher days ahead in the biotech landscape.

The ability to adapt to new trends and build dedicated teams for emerging markets is crucial for venture firms to remain competitive in a rapidly evolving landscape.

We launched our product online, supported it via email, and maintained a frugal, cash-neutral operation while reaching an international market from the start.

Our approach to doing things unscalably continued even after raising the seed round, focusing on rapid growth and execution.